Sandostatin

Acromegaly, Flushing, Gastroenteritis + 4 more
Treatment
6 FDA approvals
16 Active Studies for Sandostatin

What is Sandostatin

OctreotideThe Generic name of this drug
Treatment SummaryAcromegaly is a disorder caused by too much growth hormone, resulting in abnormal growth in certain parts of the body, such as the face, hands, and feet. In most cases, it is caused by a tumor in the pituitary gland. Octreotide is a drug that mimics the natural hormone somatostatin to reduce growth hormone production. It's used to treat acromegaly and other tumor-related symptoms, and is usually given as an injection. On June 26, 2020, the first approved oral form of octreotide, called Mycapssa, was approved for long-term treatment of
Octreotide Acetateis the brand name
image of different drug pills on a surface
Sandostatin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Octreotide Acetate
Octreotide
1988
89

Approved as Treatment by the FDA

Octreotide, otherwise known as Octreotide Acetate, is approved by the FDA for 6 uses such as Gastroenteritis and metastatic Carcinoid Tumors .
Gastroenteritis
metastatic Carcinoid Tumors
Diarrhea
Carcinoid Tumor
Acromegaly
Helps manage Acromegaly
Flushing

Effectiveness

How Sandostatin Affects PatientsOctreotide is a drug that works similar to the hormone somatostatin. It helps to control growth hormone and insulin levels in people with acromegaly, as well as reducing flushing and diarrhea caused by tumors in the digestive system. However, it can also reduce gallbladder contractility, bile secretion, and the release of thyroid-stimulating hormones in healthy people. There have also been reports that it can lower vitamin B12 levels, so it is important to monitor this in patients taking octreotide.
How Sandostatin works in the bodyOctreotide works to reduce the effects of hormones that cause growth and other metabolic changes. It does this by binding to receptors in the blood vessels, which causes the muscles to contract. This process then leads to reduced growth hormone secretion, as well as a decrease in other hormones like luteinizing hormone (LH). Octreotide also reduces symptoms associated with carcinoid and VIPoma tumors, such as flushing and gastrointestinal distress.

When to interrupt dosage

The proposed amount of Sandostatin is contingent upon the determined condition, including Acromegaly, Vasoactive Intestinal Peptide Tumors and metastatic Carcinoid Tumors. The quantity of dosage fluctuates as per the technique of delivery (e.g. Injection - Intravenous; Subcutaneous or Capsule, delayed release) displayed in the table beneath.
Condition
Dosage
Administration
Flushing
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Carcinoid Tumor
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
octreotide
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Acromegaly
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Gastroenteritis
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
long-term maintenance therapy
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular
Vasoactive Intestinal Peptide Tumors
, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL
Intravenous; Subcutaneous, Injection, solution, , Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Kit - Intramuscular

Warnings

Sandostatin Contraindications
Condition
Risk Level
Notes
known hypersensitivity to the drug or any of the ingredients
Do Not Combine
There are 20 known major drug interactions with Sandostatin.
Common Sandostatin Drug Interactions
Drug Name
Risk Level
Description
Dotatate gallium Ga-68
Major
Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Octreotide.
Fentanyl
Major
The metabolism of Fentanyl can be decreased when combined with Octreotide.
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.
Lutetium Lu 177 dotatate
Major
The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.
Sandostatin Toxicity & Overdose RiskTaking too much octreotide can cause low blood pressure, lack of oxygen to the brain, irregular heartbeat, and heart failure. Other side effects include high levels of lactic acid in the blood, inflammation of the pancreas, enlargement of the liver, diarrhea, redness of the skin, fatigue, and weakness.
image of a doctor in a lab doing drug, clinical research

Sandostatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Sandostatin?

41 active trials are currently being conducted to examine the potential of Sandostatin to treat metastatic Carcinoid Tumors, provide long-term maintenance therapy and reduce Flushing symptoms.
Condition
Clinical Trials
Trial Phases
Acromegaly
5 Actively Recruiting
Phase 3, Phase 2
Flushing
0 Actively Recruiting
Gastroenteritis
12 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Early Phase 1
Vasoactive Intestinal Peptide Tumors
0 Actively Recruiting
Carcinoid Tumor
1 Actively Recruiting
Early Phase 1
long-term maintenance therapy
0 Actively Recruiting
octreotide
0 Actively Recruiting

Sandostatin Reviews: What are patients saying about Sandostatin?

5Patient Review
5/27/2009
Sandostatin for Carcinoid Syndrome
I was diagnosed with carcinoid tumors in May 2007 and have been receiving shots from an oncologist since June 2007. So far, the treatment seems to be working well.
5Patient Review
5/19/2010
Sandostatin for Carcinoid Syndrome
I've been getting this treatment every 28 days and it's been working really well so far. I have noticed that my blood sugar levels fall sometimes after the injection, which can make me feel shaky. But overall, it's been a positive experience and I'm glad I checked it out.
5Patient Review
4/1/2010
Sandostatin for Carcinoid Syndrome
This drug worked great for my initial problem, but I developed some serious side effects. I had to have my gall bladder removed, and now my glucose is rising each month. Fingers crossed that I don't develop diabetes as a result.
5Patient Review
4/11/2015
Sandostatin for Carcinoid Syndrome
From my experience, this drug does not mix well with warfarin.
4.7Patient Review
12/26/2008
Sandostatin for Syndrome After Rapid Passage of Food Into Small Intestine
I was having four bouts of diarrhea a day, but this medication has brought that number down to just one.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about sandostatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Sandostatin a chemotherapy?

"Sandostatin is not a chemotherapy drug. It is a man-made hormone that has similar effects to somatostatin, a hormone produced naturally in our bodies."

Answered by AI

What is the side effects of Sandostatin?

"The six most common symptoms of Covid-19 are: back pain, fatigue, headache, abdominal pain, nausea, and dizziness."

Answered by AI

What is the drug Sandostatin used for?

"Sandostatin and Sandostatin LAR Depot are FDA-approved drugs used to treat severe diarrhea and flushing (a feeling of warmth and redness in your skin) caused by metastatic carcinoid tumors. Carcinoid tumors are a type of cancer that usually starts in your lungs or digestive system."

Answered by AI

What is octreotide Sandostatin used for?

"Octreotide is used to treat symptoms caused by certain types of tumors, such as severe watery diarrhea, sudden reddening of the face and neck, that are usually found in the intestines and pancreas."

Answered by AI

Clinical Trials for Sandostatin

Have you considered Sandostatin clinical trials? We made a collection of clinical trials featuring Sandostatin, we think they might fit your search criteria.
Have you considered Sandostatin clinical trials? We made a collection of clinical trials featuring Sandostatin, we think they might fit your search criteria.
Have you considered Sandostatin clinical trials? We made a collection of clinical trials featuring Sandostatin, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top